Biologic Therapies Approved for the Treatment of Generalized Myasthenia Gravis - Part 2
In the final episode of this two-part series, Dr. Joe Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized…
Read the full articleYou might also wanna read
EAN 2026: Positive trial data for cemdisiran underscores potential for use in generalized MG, says GlobalData
On June 30, at the 12th Congress of the European Academy of Neurology (EAN) 2026, Regeneron announced the results from an additional analysi
Complete Remission of Cavin-4 Immunoglobulin G Rippling Muscle Disease After Rituximab Therapy
This case report describes a 65-year-old man who experienced complete remission of cavin-4 immunoglobulin G (IgG) rippling muscle disease af
doi.org·14d ago
Unequal Access to New Myasthenia Gravis Therapies Across Europe Highlights Healthcare Disparities
New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues to hold patien
euractiv.com·21d agoUConn Health Minute: Managing Myasthenia Gravis
Myasthenia gravis is a chronic condition caused by the immune system attacking the body. UConn Health’s neuromuscular team has the expertise
Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Conditions : Autoimmune Encephalitis (AE); Autoimmune Cerebellitis Interventions : Drug: Blinatumomab Sponsors : Beijing Tiantan Hospital No
Megan’s Myasthenia Gravis Story: From Uncertainty to Advocacy
I was diagnosed with myasthenia gravis, or MG, in 2021 when I was in my early 20s. My journey began at a friend’s birthday party when I noti
Comments
Sign in to join the conversation.
No comments yet. Be the first.